Consumer-Grade vs. Medical-Grade Devices: What You Need to Know to Improve Study Outcomes

Consumer-grade devices and sensors offer improved quantitative endpoints to advance clinical trials and other medical studies. However, study leads often lack the necessary proof points. This webinar seeks to empower study decision-makers to make informed decisions around devices and sensors that will increase the likelihood of study success. Following an overview of consumer device and medical device markets, this webinar will address:

• How activity trackers produce step algorithms
• How accelerometers work
• The strengths and weaknesses of sensors and their data flows

Speakers

Paul W. Glimcher, PhD, President & Chief Executive Officer, Datacubed Health

Paul Glimcher is a neuroscientist, psychologist, economist and entrepreneur who holds the Julius Silver, Rosyln S. Silver and Enid Silver Winslow Professorship at New York University (NYU). He is also a professor in the department of neuroscience and physiology of the neuroscience institute at NYU Langone School of Medicine. Professor Glimcher is the founder and director of NYU’s Institute for the Study of Decision Making, and the principal investigator of Glimcher Lab at NYU Langone Health. Professor Glimcher is one of the foremost researchers focused on the study of human behavior and decision-making and is known for his central role in founding and developing the field of neuroeconomics which takes an interdisciplinary approach to understand how humans make decisions. Professor Glimcher’s research aims to describe the neural events that underlie behavioral decision-making using tools from economics, psychology and neuroscience. His research has made contributions to understanding how value is encoded in the brain and how the brain uses those neural representations of value to guide decision-making.

Message Presenter

Jennifer Cho, PharmD, Deputy Chief Scientific Officer, Datacubed Health

Jennifer has extensive clinical trials experience and expertise, having worked in Clinical Operations and Clinical Science at Novartis and Celgene, and as a study coordinator at Dana-Farber Cancer Institute and an academic ambulatory pediatric clinic. Her experience spans Phase 1-3 trials, including positive pivotal studies that gained regulatory approvals such as the ASCEND-4 study (ceritinib in 1st line ALK+ non-small cell lung cancer). Jennifer received her Bachelor of Arts in Child Development and Community Health from Tufts University and her Doctor of Pharmacy from the University of Maryland School of Pharmacy, and is a licensed pharmacist in New York and New Jersey.

Message Presenter